HedgeChatter

  • Home /
  • Tag Archives

DYAX

Dyax Corp. Announces Fourth Quarter and Full Year 2013 Financial Results

[Business Wire] – Dyax Corp. today announced financial results for the fourth quarter and year ended December 31, 2013. Dyax will host a webcast and conference call at 8:30 a.m. moreView todays social media effects on DYAXView the latest stocks trending across Twitter. Click to view dashboardSee who Dyax is hiring next, click here to view […]

February 28, 2014 Bystocknews , Comments Off on Dyax Corp. Announces Fourth Quarter and Full Year 2013 Financial Results read more

Dyax’s Management Presents at DX-2930 Phase 1a Data Review Conference (Transcript)

[at Seeking Alpha] – Burt A. Adelman Thank you, Jen. Good afternoon, and welcome to Dyax’s presentation of the results of our Phase 1a study DX-2930. As Jen mentioned I am Burt Adelman, Dyax’s Executive Vice President of Research … moreView todays social media effects on DYAXView the latest stocks trending across Twitter. Click to view dashboardSee who Dyax is […]

February 27, 2014 Bystocknews , Comments Off on Dyax’s Management Presents at DX-2930 Phase 1a Data Review Conference (Transcript) read more

Dyax Corp. to Participate in the 2014 Cowen and Company 34th Annual Health Care Conference

[Business Wire] – Dyax Corp. announced today that executive management will participate in the 2014 Cowen and Company 34th Annual Health Care Conference being held March 3-5, 2014 at the Boston Marriott Copley Place in Boston, MA. moreView todays social media effects on DYAXView the latest stocks trending across Twitter. Click to view dashboardSee who Dyax is hiring next, click […]

February 26, 2014 Bystocknews , Comments Off on Dyax Corp. to Participate in the 2014 Cowen and Company 34th Annual Health Care Conference read more

Dyax price target raised to $12 from $8 at Leerink

moreView todays social media effects on DYAXView the latest stocks trending across Twitter. Click to view dashboardSee who Dyax is hiring next, click here to view […]

February 26, 2014 Bystocknews , Comments Off on Dyax price target raised to $12 from $8 at Leerink read more

Dyax Announces Positive Results from Phase 1a Clinical Trial of DX-2930

[Business Wire] – Dyax Corp. today announced positive results from the first-in-human clinical study of their investigational product, DX-2930. The Phase 1a study met all objectives of assessing safety, tolerability and pharmacokinetics of DX-2930. moreView todays social media effects on DYAXView the latest stocks trending across Twitter. Click to view dashboardSee who Dyax is hiring next, click here to view […]

February 25, 2014 Bystocknews , Comments Off on Dyax Announces Positive Results from Phase 1a Clinical Trial of DX-2930 read more

Dyax Corp. to Host Fourth Quarter and Year End 2013 Earnings Call and Webcast

[Business Wire] – Dyax Corp. will host a webcast and conference call, including an open question and answer session, Friday, February 28, 2014. During the call, management will discuss moreView todays social media effects on DYAXView the latest stocks trending across Twitter. Click to view dashboardSee who Dyax is hiring next, click here to view […]

February 13, 2014 Bystocknews , Comments Off on Dyax Corp. to Host Fourth Quarter and Year End 2013 Earnings Call and Webcast read more

Dyax Corp. and CVie Therapeutics Announce Partnership to Develop and Commercialize KALBITOR® (ecallantide) for Hereditary Angioedema (HAE) and Other Angioedema Indications in China, Hong Kong and Macau

[Business Wire] – BURLINGTON, Mass. & HONG KONG–(BUSINESSWIRE)– Dyax Corp. (NASDAQ: DYAX ), a developer of novel biotherapeutics for unmet medical needs, and CVie Therapeutics (CVie), a subsidiary of Lee’s Pharmaceutical … moreView todays social media effects on DYAXView the latest stocks trending across Twitter. Click to view dashboardSee who Dyax is hiring next, click here to view […]

February 7, 2013 Bystocknews , Comments Off on Dyax Corp. and CVie Therapeutics Announce Partnership to Develop and Commercialize KALBITOR® (ecallantide) for Hereditary Angioedema (HAE) and Other Angioedema Indications in China, Hong Kong and Macau read more